Close menu

July 21st, 2020 | 14:17 CEST

dynaCERT, EXMceuticals, - waiting for the turnaround

  • Turnaround
Photo credits:

Investors usually assume that their investment should increase from the time they enter the market. The sellers of the shares have already given up this hope or they see the potential as limited, but sometimes it is also personal circumstances that contribute to a decision to sell. As soon as the demand for a company's shares exceeds the supply, the value will usually rise. Usually, positive news about an industry or a company is the trigger for a renewed increase in interest.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA26780A1084 , CA30207T1049 , DE000WNDL201

Table of contents:

    Waiting for success messages

    The dynaCERT share price reached a high of CAD 1.25 last February. In the following month of March, however, the value of the shares of the hydrogen retrofitter dropped to below CAD 0.33. Covid-19 brought the economy around the globe to a standstill and investors' expectations for the future clouded heavily. Just two months later, the shares changed hands again at CAD 0.94. At the moment the share is traded at around CAD 0.53 and thus at the level of the fourth quarter of 2019.

    Investors are now waiting for success stories about sales figures or the future potential of the technology. In recent months, the company and its employees have been comparatively restricted, like most people in North America and Europe. With increasing easing and the recovery of the economy, positive news from dynaCERT should be heard again. The company has developed a retrofit technology that uses hydrogen as a catalyst for diesel engines. According to dynaCERT, this increases efficiency, resulting in lower fuel consumption and reduced emissions of pollutants.

    A supplier in the making

    EXMceuticals is focused on the processing of cannabis in Portugal. The strategy is to strategically position itself with its operational and commercial development to create value through numerous vertical markets and a wide range of cannabinoid formulations. The value of EXMceuticals' stock was around CAD 0.40 at the beginning of the year and closed yesterday at CAD 0.325.

    "The demand will explode in the next few years as the European cannabis industry continues to develop into one of the largest cannabis markets in the world and more countries require the use of EU GMP standards. Securing valuable sources of ingredients with consistent, large-scale suppliers such as Plena Global is more important than ever for the buildout of the EXM supply chain.(...)", says Jonathan Summers, Chief Executive Officer of EXM, in a recent statement.

    The eCommerce turnaround story

    On 14 August 2020 will publish the results of the second quarter 2020. In connection with the restrictions to contain the Corona Pandemic, it is expected that the sales development of the eCommerce company will reflect that the online activities of existing and new customers have increased.

    The company's share price was EUR 1.34 at the beginning of the year and has since risen to EUR 6.80. Currently the shares change hands at EUR 2.00. It will be exciting to see which details can attract the interest of investors on August 14, 2020.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Armin Schulz on July 27th, 2023 | 07:15 CEST

    BioNTech, Defiance Silver, Vonovia - Waiting for the turnaround

    • Mining
    • Silver
    • Turnaround
    • Biotechnology
    • RealEstate

    The stock market is not a one-way street, so it happens time and again that companies that initially performed well run into problems, leading to falling prices. After an extended period of underperformance, bargain hunters often step in, seeking the right entry point to profit from a potential turnaround. One announcement can turn the tide and influence the price of a stock. We have selected three candidates where a turnaround could be imminent, provided an appropriate news catalyst exists.


    Commented by André Will-Laudien on December 15th, 2022 | 12:09 CET

    100% turnaround opportunities for 2023: TUI, Uniper, Desert Gold, FlatexDEGIRO - The New Year's Eve bangers!

    • Mining
    • Gold
    • Investments
    • Turnaround

    Despite all the gloom, the capital market offers plenty of new opportunities every day. Although the DAX is holding up well at the end of the year, many shares have crashed and remain at the bottom of the charts for the time being. But there are some glimmers of hope. Many investors sell poorly performing shares at the end of the year in order to benefit from the tax write-off of losses. The lucky investors even have a few profits to offset and like to smooth out the underperformers at year-end. Shares in Uniper, TUI and FlatexDEGIRO have slumped between 40% and 90% this year, but there are bright spots for 2023.


    Commented by Nico Popp on October 17th, 2022 | 12:21 CEST

    Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?

    • Biotechnology
    • Turnaround

    After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.